GALDERMA
Galderma, a global specialty pharmaceutical company focused on dermatology, announced today a positive outcome of the European Decentralised Procedure (DCP) for SOOLANTRA® (ivermectin) Cream 10mg/g for the once-daily topical treatment of inflammatory lesions of papulopustular rosacea in adult patients. The Medical Products Agency (MPA) in Sweden acted as Reference Member State (RMS) on behalf of 28 EU Member States, which all agreed that SOOLANTRA Cream can be approved.
“As a world leader in skin health, Galderma is committed to providing innovative treatment options for clinicians and patients, and the approval of SOOLANTRA Cream highlights our continuous efforts,” said Stuart Raetzman, CEO of Galderma Pharma SA. “A clear focus on skin health has helped us expand our rosacea franchise to deliver more medicines that offer a novel approach, addressing important patient needs.”
The Marketing Authorisation application of SOOLANTRA Cream was based on three Phase III studies, which involved over 2,300 subjects. Two 12-week treatment vehicle-controlled studies demonstrated superiority of SOOLANTRA Cream efficacy over vehicle cream within 4 weeks. In a 16-week treatment active-controlled study, SOOLANTRA Cream was shown to be superior to Metronidazole 7.5 mg/g cream twice-daily in reducing Inflammatory Lesion Counts (ILC) as of Week 3 and until Week 16. After 16 weeks of treatment with SOOLANTRA, the reduction in ILC reached 83.0% from baseline. This is reflected in the European prescribing information.
While the SOOLANTRA Cream mechanism of action is not completely understood, ivermectin – its active ingredient – has been reported to have both anti-inflammatory and anti-parasitic properties.
“There are currently few effective treatments that reduce the papules and pustules of rosacea, and these may take in excess of four weeks to show results,” commented Jürgen Schauber, MD, Ludwig-Maximilian University, Munich, Germany. “SOOLANTRA Cream has demonstrated a quick onset and improved efficacy over an existing reference treatment in clinical studies, making it a new therapeutic option that meets the needs of rosacea patients.”
About Rosacea
Rosacea is a common inflammatory skin disease that presents variable clinical characteristics, of which the most common are flushing, permanent erythema, papules and pustules. It mainly affects the central areas of the face, such as the cheeks and nose. The disease affects both adult men and women, usually after the age of 30. Additionally, symptoms such as stinging, burning and increased sensitivity of the skin are common, and in some cases the eyes can become red, dry and itchy.
Although the cause of the disease is still under debate, various trigger factors are known, including spicy foods, alcohol, emotional stress, sun/UV-exposure, hot baths and beverages. Demodex, generally harmless mites, can also be found in the skin in an elevated quantity in people with rosacea.
Rosacea may worsen over time if left untreated. People that suspect they suffer from rosacea should visit their dermatologist or healthcare provider for diagnosis, and discuss what treatment is right for them. Because rosacea is a highly visible disease, it is known to cause embarrassment and anxiety in some patients, which in turn may cause frustration and have a negative impact on their social life.
About Galderma
Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime, while serving healthcare professionals around the world. The company has 34 wholly-owned affiliates with a worldwide network of distributors and more than 5,500 employees. Galderma’s extensive product portfolio is available in 80 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis and steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.
Galderma is the operating company of Nestlé Skin Health, a global leader focused on enhancing the quality of life by delivering science-based solutions for the health of skin, hair and nails. Five state-of-the-art R&D centers and six manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.
Strategic Galderma brands include Epiduo® , Oracea® , Differin® , Mirvaso® , Soolantra® , Tri-Luma® , Loceryl® , Cetaphil® , Metvix® , Azzalure® / Dysport® , Restylane® and Emervel® .
For more information, please visit Galderma’s website: www.galderma.com
Contact:
Media
Galderma
Sébastien Cros, +33 1 58 86 45 92
media@galderma.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Andersen Consulting forbedrer sine organisatoriske udviklingskapaciteter med Omni HR Consulting1.8.2025 19:22:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for menneskelige ressourcer gennem en samarbejdsaftale med Omni HR Consulting, et sydafrikansk konsulentfirma med speciale i løsninger til forretnings- og personaleudvikling. Omni HR Consulting tilbyder en komplet pakke af tjenester, der omfatter organisationsudvikling, præstationsrådgivning, akkrediteret uddannelse, kompetenceudvikling og ledelsesprogrammer gennem sit Business and Leadership Academy. Virksomheden samarbejder med kunderne om at designe og implementere løsninger, der retter sig mod medarbejdernes kompetencer, optimering af resultater og strategisk tilpasning og understøttes af en konsekvent tilgang til projektledelse og overholdelse af sydafrikanske kvalitetsstandarder. "Hos Omni tror vi på, at effektiv udvikling starter med forståelse af konteksten," siger administrerende direktør Lize Moldenhauer. "Vi arbejder tæt sammen med vores kunder for at udvikle skræddersyede løsninger, der skaber målbare fremskridt – hvad ente
DevvStream Deploys Crypto Treasury with Initial Bitcoin and Solana Purchases; Intends to Expand Credit Facility to $300M1.8.2025 16:00:00 CEST | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced the initial deployment of its crypto treasury strategy with purchases of Bitcoin ($BTC) and Solana ($SOL), funded by a portion of the first (US)$10 million tranche of its (US)$300 million senior secured convertible notes facility with Helena Global Investment Opportunities 1 Ltd. These acquisitions represent the operational launch of DevvStream’s digital treasury strategy, designed to combine institutional-grade liquidity with blockchain infrastructure. The Company believes Bitcoin provides a liquid, non-correlated store of value and that Solana’s high-throughput network supports the Company’s long-term objectives in, and the industry’s move towards, sustainability-linked tokenization. In parallel, DevvStream announced its intention to increase its existing Equity Line of Credit (ELOC) to (US)$30
BEYOND Launches PASSO, a Sculptural Icon on Palm Jumeirah1.8.2025 15:17:00 CEST | Press release
BEYOND Developments, the forward-thinking real estate brand shaping lifestyle destinations by the sea, has unveiled PASSO, a sculptural waterfront development located on the prestigious West Crescent of Palm Jumeirah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250801880717/en/ PASSO by BEYOND, a Sculptural Icon on Palm Jumeirah. (Photo: AETOSWire) As BEYOND’s first flagship beyond its masterplan in Dubai Maritime City, PASSO marks a defining milestone in the company’s strategic growth to one of the world’s most iconic and desirable destinations. The project launched with a spectacular Palm Jumeirah event featuring Dubai’s first-ever “screens in the sky” show, a 13-minute performance with over 4,000 drones blending immersive visuals and live stage action. Comprising two sculptural towers, Avita and Bella, PASSO offers 625 residences in a refined mix of layouts. From one-bedroom retreats and two-to-four-bedroom-plus lifest
LevelBlue Completes Acquisition of Aon’s Cybersecurity and IP Litigation Consulting Groups1.8.2025 14:00:00 CEST | Press release
Strategic deal enhances LevelBlue's cybersecurity offerings, solidifying its position as the world’s largest leading independent, pure-play MSSP LevelBlue, a global leader in cloud-based, AI-driven managed security services, today announced the completion of its acquisition of Aon’s (NYSE: AON) Cybersecurity and Intellectual Property (IP) Litigation consulting groups, including the renowned cybersecurity firm, Stroz Friedberg, and Elysium Digital. With this completion the consulting group will operate as Stroz Friedberg, a LevelBlue company. This strategic acquisition adds elite cyber and high-tech IP litigation consulting expertise to the LevelBlue portfolio, which includes a globally recognized platform of approximately 300 technology professionals with deep relationships across Fortune 500 companies, 80 percent of the Am Law 100, and most of the UK’s top 20 law firms. As a result, LevelBlue will significantly fortify its incident response and advisory capabilities, while expanding i
SBC Medical to Announce Q2 2025 Financial Results and Hold Conference Call on August 13, 20251.8.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global franchise and provider of services for aesthetic clinics, today announced that it will report its Q2 2025 financial results on Wednesday, August 13, 2025, before the U.S. market opens. The Company will hold a conference call on Wednesday, August 13, 2025 at 8:30 am Eastern Time (or Wednesday, August 13, 2025 at 9:30 pm Japan Time) to discuss the financial results and take questions live. Please register in advance of the conference using the link provided below. https://edge.media-server.com/mmc/p/ukc9sp9j It will automatically direct you to the registration page of “SBC Q2 2025 Financial Results Presentation.” Please follow the steps to enter your registration details, then click “Submit.” Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well a
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum